Orgovyx Tablet, Film Coated
Product Images NDC 72974-120

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Orgovyx (NDC 72974-120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sumitomo Pharma America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Orgovyx 01)

FDA Label Image

Figure 1 (Orgovyx 02)

FDA Label Image

Figure 2 (Orgovyx 03)

Figure 2 (Orgovyx 03)
Not available. The text provided seems to be incomplete and does not provide any meaningful information.*
FDA Label Image

Figure 3 (Orgovyx 04)

Figure 3 (Orgovyx 04)
This text describes the cumulative incidence of time to achieve a testosterone level of less than 50 ng/dL in patients treated with two different medications, Relugolix and Leuprolide. The text includes a chart with the number of patients at risk for each medication at various points in time.*
FDA Label Image

Figure 3 (Orgovyx 05)

Figure 3 (Orgovyx 05)
The text represents a chart or graph showing the cumulative incidence of time for testosterone to be less than 20 ng/dL for two different treatments, Regulix and Leuprolide, over a period of weeks. The number of patients at risk for each week is also shown. Therefore, the chart is useful for analyzing the effectiveness of these treatments in reducing testosterone levels.*
FDA Label Image

Principal Display Panel (120 mg Tablet Bottle Label)

Principal Display Panel (120 mg Tablet Bottle Label)
This is a medication called ORGOVYX, which comes in tablet form with a recommended dosage that can be found in the prescribing information. It should be kept out of reach of children and stored at room temperature, but not above 30°C. The medication is distributed by Myovant Sciences and manufactured by Bushu Pharmaceuticals in Japan, but is a product of Germany. The medication is available in a package of 30 tablets, with each tablet containing 120 mg of relugolix. The NDC number for this product is 72974-120-01 and it is only available with a prescription (Rxonly).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.